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Background: The antiretroviral nevirapine is associated with hypersensitivity reactions in 6%–10% of patients,
including hepatotoxicity, maculopapular exanthema, Stevens–Johnson syndrome (SJS) and toxic epidermal nec-
rolysis (TEN).
Objectives: To undertake a genome-wide association study (GWAS) to identify genetic predisposing factors for
the different clinical phenotypes associated with nevirapine hypersensitivity.
Methods: A GWAS was undertaken in a discovery cohort of 151 nevirapine-hypersensitive and 182 tolerant,
HIV-infected Malawian adults. Replication of signals was determined in a cohort of 116 cases and 68 controls
obtained from Malawi, Uganda and Mozambique. Interaction with ERAP genes was determined in patients posi-
tive for HLA-C*04:01. In silico docking studies were also performed forHLA-C*04:01.
Results: Fifteen SNPs demonstrated nominal significance (P,1%10#5) with one or more of the hypersensitivity
phenotypes. The most promising signal was seen in SJS/TEN, where rs5010528 (HLA-C locus) approached
genome-wide significance (P,8.5%10#8) and was below HLA-wide significance (P,2.5%10#4) in the
meta-analysis of discovery and replication cohorts [OR 4.84 (95% CI 2.71–8.61)]. rs5010528 is a strong proxy for
HLA-C*04:01 carriage: in silico docking showed that two residues (33 and 123) in the B pocket were the most
likely nevirapine interactors. There was no interaction between HLA-C*04:01 and ERAP1, but there is a potential
protective effect with ERAP2 [P"0.019, OR 0.43 (95% CI 0.21–0.87)].
Conclusions: HLA-C*04:01 predisposes to nevirapine-induced SJS/TEN in sub-Saharan Africans, but not to other
hypersensitivity phenotypes. This is likely to be mediated via binding to the B pocket of the HLA-C peptide.
Whether this risk is modulated by ERAP2 variants requires further study.
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Introduction
Nevirapine, an NNRTI used for HIV1 infection is effective2 as part
of combination antiretroviral therapy, but causes hypersensitivity
in 6%–10% of patients.3,4 This can manifest in various ways, rang-
ing from nevirapine-induced rash (NIR) (i.e. a maculopapular
exanthema without any systemic manifestations), hypersensitiv-
ity syndrome (HSS) to severe blistering skin reactions such as
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN)5 (1–2 per 1000 exposed individuals6). Extra-cutaneous
involvement typically manifests as hepatotoxicity.7
Identification of the genetic risk factors for nevirapine hyper-
sensitivity has focused on candidate gene approaches. Nevirapine
is primarily metabolized by the hepatic cytochrome P450s 2B6
(CYP2B6) and 3A4 (CYP3A4).8 The exon 4 variant in CYP2B6
(c.516G. T), which encodes a non-synonymous amino acid sub-
stitution (Gln172His) (rs3745274), leads to loss of function,9,10
with the variant T allele resulting in higher nevirapine plasma con-
centrations in both Caucasian11 and sub-Saharan12 adult pa-
tients. The associations with CYP2B6 polymorphisms are rather
confusing with the CYP2B6 c.516G. T SNP associated with
nevirapine-induced cutaneous adverse events in black and white
populations13 but not with nevirapine-induced hepatotoxicity.14
The association with HLA alleles is even more complex, with HLA-
DRB1*01:01 (Caucasian13,15,16), HLA-C*04 (Thai,17 Chinese18 and
Black13), HLA-C*08 (Japanese19) and HLA-B*35:05 (Thai13,20)
acting as predisposing alleles for nevirapine hypersensitivity. Our
own previous study within a subset of patients from the Malawian
HIV population described in this paper identified an association
betweenHLA-C*04:01 and nevirapine-induced SJS.21
In this study, in order to overcome some of the issues associ-
ated with candidate gene analysis, we have undertaken a gen-
ome-wide association study (GWAS) in a Malawian HIV cohort of
nevirapine-exposed patients in order to identify genetic bio-
markers of nevirapine hypersensitivity in an unbiased manner. We
have also investigated whether there is any interaction between
HLA-C*04:01 in SJS/TEN patients and the endoplasmic reticulum
aminopeptidase genes (ERAP1 and ERAP2), which have been
shown to modulate the risk of various immune diseases, in particu-
lar ankylosing spondylitis.22
Methods
Patients
Discovery cohort
Antiretroviral-naive patients (n"1117) were prospectively recruited as pre-
viously described21 (Figure 1) from the Queen Elizabeth Central Hospital
(QECH), Blantyre, Malawi, between March 2007 and December 2008. All
were self-reported black African, over the age of 16, and had no baseline
jaundice. CD4! counts and liver function tests were monitored at 0, 2, 6,
10, 14, 18 and 22 weeks. Fifty-seven patients from this prospective cohort
had nevirapine-induced hypersensitivity fulfilling the criteria of one or more
of the following phenotypes:
• NIR: widespread maculopapular exanthema with no systemic mani-
festations but which worsened on treatment continuation.
• HSS: widespread rash with systemic manifestations (i.e. fever, cough or
abnormal liver function tests). This is also known as DRESS (drug reac-
tion with eosinophilia and systemic symptoms).
• SJS: blistering eruption affecting,10% of body surface area with two or
more mucous membranes involved.
• TEN: blistering rash affecting .30% of body surface area and two
or more mucous membranes. Patients with overlap syndrome had
10%–30% of their body surface area affected.
• Drug-induced liver injury (DILI): jaundice and abnormal ALT.
In addition, a total of 149 cases of nevirapine-induced hypersensitivity
were recruited prospectively from QECH separately from the study
described above, and a further 28 were identified retrospectively from pa-
tient records at the same centre. Out of a total of 234 hypersensitive cases,
159 where sufficient genomic DNA was available were included, along with
193/1060 of the nevirapine-treated age- and gender-matched controls
(352 in total), in the discovery GWAS. Numbers of tolerant controls included
were constrained by DNA quality and quantity.
Replication cohort
We recruited a number of patients with nevirapine hypersensitivity, with dif-
ferent phenotypes, from a number of centres (Table 1) to replicate our
findings:
• Thirty nevirapine-hypersensitive patients and matched (age and gen-
der) HIV-positive nevirapine-treated controls from Malawi. All controls
and eight of the cases were from the original study but not included in
the initial GWAS due to DNA quantity restraints. The other 22 cases pre-
senting with the hypersensitivity phenotype according to the above cri-
teria were identified from the QECH after the conclusion of the initial
recruitment phase (December 2008).
• Thirty-two nevirapine-hypersensitive cases and age- and gender-
matched controls identified in Uganda from the DART study cohort.23
Cases were defined according to available patient records and subse-
quently categorized into the sub-phenotypes described above.
• Twenty-seven pregnant female patients with nevirapine-induced hep-
atotoxicity and 10 nevirapine-tolerant pregnant controls from
Mozambique. Cases were defined as previously stated,24 and included
patients who discontinued nevirapine due to increased liver enzymes
(grade 3/4). Controls were excluded if ALT/AST levels exceeded the me-
dian value observed in the case cohort.
• Twenty-seven female patients with nevirapine-induced SJS/TEN from
Mozambique.25 In this instance SJS/TEN was defined as development
of exanthema and blistering starting mainly on the trunk, involving
10% of the body surface with mucosal involvement.
Ethics
Full ethics approval for the study was received from the Liverpool School of
Tropical Medicine Research Ethics Committee (Liverpool, UK), the College of
Medicine Research and Ethics Committee, University of Malawi (Blantyre,
Malawi) and the Uganda National Council for Science and Technology. All
patients gave their written informed consent and those who met the crite-
ria for a case had nevirapine withdrawn in accordance with Malawian
National Treatment Guidelines. Local ethics approval was obtained for the
DART study as previously described23 with subsequent ethics approval for a
pharmacogenetic sub-study also obtained.26
DNA extraction
Genomic DNA was extracted from whole blood for the discovery cohort21
and replication cohorts as previously described.24,25
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Discovery cohort genotyping and sample quality control
(QC)
A total of 352 samples were genotyped for 1 048 713 variants using the
HumanOmni1-Quad_v1 chip (Illumina). Variants were excluded from ana-
lysis if their minor allele frequency (MAF) was,1%, the call rate was,99%
for an MAF between 1% and 3%, the call rate was ,98% for an MAF of
.3%, or if Hardy–Weinberg expectations were not satisfied (P,10#4).
Individuals were excluded if the sample call rate was ,95%, the as-
signed gender contradicted genetic information from the X chromosome
heterozygosity, or if they appeared to be duplicates, or related to other indi-
viduals in the study (as measured by identity by state using PLINK27).
Multidimensional scaling analysis of genotype data was undertaken by
merging the data with HapMap3 cohort data and using the mds function in
PLINK27 in order to determine population stratification (Figure S1, available
as Supplementary data at JACOnline).
Discovery cohort imputation
Imputation of genotypes, after phasing of each chromosome using
ShapeIt,28 was carried out using IMPUTE V2.3.1,29 1000G phase 1 inte-
grated v3 macGT1 reference panel haplotypes (March 2012).30 After imput-
ation, SNPs with an information measure (info score),0.8 were discarded,
and a threshold of 0.5 was applied on genotype uncertainty. Imputed vari-
ants with an MAF,1% were then excluded.
Discovery cohort association analysis
Univariate logistic regression analysis of non-genetic covariates (age, gen-
der, BMI, CD4! cell count) was undertaken for each hypersensitivity pheno-
type. Statistically significant variables (P,0.05) were included in the
subsequent logistic regressions to test for the association of each hypersen-
sitivity phenotype with each SNP passing QC. All statistical analyses were
undertaken using PLINK27 and R.31 Given prior associations between nevira-
pine hypersensitivity and HLA allele associations, it was felt reasonable to
specify a Bonferroni-corrected HLA-wide significance threshold of
P,2.5%10#4, based on the presumption that there are usually ,200 ef-
fective HLA allele tests.
Replication cohort genotyping, QC and association
analysis
SNPs determined to have a nominally significant association with a nevira-
pine hypersensitivity phenotype (P,1%10#5) in the discovery cohort were
subsequently typed in the replication cohort using either the Sequenom
MassArray iPLEX platform (Sequenom Inc., San Diego, CA, USA) or custom
TaqMan real-time PCR SNP genotyping assays (Life Technologies, Paisley,
UK) according to the manufacturer’s protocols. SNPs were excluded if they
failed to meet the genotype QC thresholds as outlined for the discovery co-
hort or if assay design software parameters prohibited their inclusion.
Logistic regression analysis of the replication cohort, including and
excluding CD4! count as a covariate, where appropriate (as determined in
the discovery cohort), was carried out. Meta-analysis of combined discovery
and replication cohorts was undertaken using a fixed-effects model with
inverse-variant effect size weighting in GWAMA.32
Imputation of HLA allelotype and MHC locus
Imputation of HLA-C allelotype from the discovery cohort SNP array data
was undertaken using HLA*IMP:0233 (see Supplementary data).
HLA-C and ERAP gene–gene interactions
In cases and tolerant controls positive for carriage of the rs5010528 G al-
lele, which was used as a proxy for HLA-C*04:01, we investigated both
ERAP1 (rs10050860 and rs30187) and ERAP2 (rs2248374, rs2549782) SNPs
DISCOVERY COHORT
REPLICATION COHORT
QECH, Malawi
Hypersensitivity
N=30
Tolerant controls
N=29
DART study, Uganda
Hypersensitivity
N=32
Tolerant controls
N=32
Mozambique
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N=27
SJS/TEN
N=27
Tolerant controls
N=8
Queen Elizabeth Central Hospital (QECH), Malawi
HIV positive clinical stage 3/4
antiretroviral-naive patients
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Tolerant
controls
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Figure 1. Schematic representation of the source of both nevirapine-hypersensitive and -tolerant patients for the GWAS discovery and replication
cohorts.
GWAS of nevirapine hypersensitivity JAC
3 of 11
(using data from the Illumina array), which have previously been shown
to interact with HLA-mediated immune diseases. Association of ERAP1
and ERAP2 SNPs with SJS/TEN risk was determined in the HLA-C*04:01-
positive cohort (cases and controls) by logistic regression with CD4! cell
count as a covariate using PLINK.27 A Bonferroni adjustment for multiple
testing was applied with a significance threshold of P"0.125.
Targeted sequencing of MHC region
Sixteen genomic DNA samples from nevirapine-induced SJS/TEN and
16 age- and gender-matched tolerant controls were carried forward for
MHC-targeted sequencing. The methodology is detailed in the
Supplementary data.
Allelotyping
HLA allelotyping was performed from raw FASTQ data files using Omixon
Target v1.81 HLA Typing software and utilized the HLA database version
3.15.0. (Omixon Ltd, Budapest, Hungary).
In silico docking
In order to predict possible modes of interaction between nevirapine and
HLA-C*04:01, in silico docking was undertaken. The methodology is de-
tailed in the Supplementary data.
Results
Discovery cohort
A total of 333 samples (151 cases and 182 controls) out of 352
passed QC. Of the 19 excluded samples, 9 failed heterozygosity
checks (outliers by .3 SD), 8 failed identity checks and 2 failed
the call rate threshold. Multi-dimensional analysis for population
stratification (Figure S1) demonstrated no population outliers.
In total, 817 728 SNPs passed QC and were carried over for im-
putation with the 1000 genomes panel. Imputation produced a
dataset of 1 421 8511 variants. Cohort characteristics are
shown in Table 1. We considered five nevirapine-induced hyper-
sensitivity phenotypes for analysis—NIR, HSS, SJS/TEN, DILI
(Table 1)—and also combined these different phenotypes into
an overall hypersensitivity group.
Univariate logistic regression analysis showed CD4! cell count
to be a statistically significant variable for NIR (P" 0.016), SJS
(P"0.003) and all hypersensitivity cases (P"2.5%10#6).
Therefore, we included CD4! cell count as a covariate in the SNP
logistic regression model for these three phenotypes.
Multidimensional scaling (MDS) variables were not included as
covariates in the logistic regression since the population stratifi-
cation analysis suggested that the cohort was homogeneous
and genomic control was unnecessary (Figure S1). From the
genome-wide logistic regression analyses, we identified 15 SNPs
with P,1%10#5, with at least one of the five different pheno-
types analysed (Figure 2; summarized in Table 2). No variant
reached genome-wide significance.
Replication cohort
Of the 15 SNPs considered for replication, one (rs150223496)
could not be typed due to proximal sequence constraints of
the Sequenom assay design process, and QC failure
for TaqMan genotyping Hardy-Weinberg equilibrium (HWE)Ta
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Figure 2. Manhattan plots of association for logistic regression SNP analysis for the five defined nevirapine hypersensitivity phenotypes. The pheno-
types, all hypersensitivity, NIR and SJS/TEN show P values from logistic regression incorporating CD4! count as a covariate. For HSS and DILI no cova-
riates were incorporated. The broken line indicates genome-wide significance (P"5%10#8).
Table 2. Top SNPs identified in association with a nevirapine hypersensitivity phenotype within the main cohort analysis
Phenotype SNP Chr
Position
(GRCh37 .p13)
Reference
allele
Associated
allele Gene
Typed/
imputed
Logistic regression
P value OR (95% CI)
All hypersensitivity
(n"151)
rs34213790 6 31318579 G A 30 of HLA-B imputed 1.15%10#6 2.34 (1.66–3.30)
rs11764223 7 137742056 T G AKR1D1 imputed 2.99%10#6 0.45 (0.33–0.63)
rs11988543 8 68596362 T A CPA6 imputed 2.69%10#6 3.37 (2.03–5.60)
rs9527426 13 56208216 T C MIR5007 typed 9.86%10#6 2.25 (1.58–3.21)
rs35990155 23 11827017 G T KIAA1210 imputed 6.33%10#7 5.65 (2.86–11.17)
Rash (n"56) rs10815440 9 661057 G A KANK1 typed 8.86%10#6 5.80 (2.68–12.67)
rs115848367 10 128045499 A C ADAM12 imputed 8.83%10#7 4.70 (2.38–9.30)
rs74373347 12 48919428 A G OR8S1 imputed 1.08%10#6 11.05 (4.12–29.04)
rs6511720 19 11202306 G T LDLR typed 5.49% 10#6 4.66 (2.40–9.05)
SJS/TEN (n"51) rs5010528 6 31241032 A G HLA-C typed 4.13%10#6 4.75 (2.45–9.22)
rs150223496 15 76421885 G A C15orf27 imputed 8.20%10#6 17.34 (4.95–60.74)
DILI (n"21) rs147773805 1 107741393 A T NTNG1 imputed 4.47%10#6 11.05 (3.96–30.83)
rs114693001 9 76074363 A T intergenic imputed 8.82%10#6 9.35 (3.49–25.06)
rs142213069 13 77962182 G C 50 of MYCBP2 imputed 6.64%10#6 14.42 (4.51–46.04)
rs6139258 20 3958616 T C RNF24 typed 6.64% 10#6 14.42 (4.52–46.04)
P values and ORs were determined by logistic regression with CD4! cell count as a covariate (except for HSS and DILI).
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P value.0.0001, call rate.90%. Thus, 14 SNPs were carried for-
ward for analysis. A total of 59 Malawian samples (30 cases and
29 controls) and 63 Ugandan samples (32 cases and 31 con-
trols) passed QC (call rate .90%) as described in Table 1. Due to
sample constraints, SNP signals identified in the discovery co-
hort for the ‘all hypersensitivity’ phenotype were not typed in
the samples from Mozambique in the replication cohort.
For nevirapine-induced DILI (Table 3), combining the discovery
and replication cohorts for the SNP rs6139258 in the RNF24 locus
strengthened the association [P"5.7%10#7, OR 13.62 (95% CI
4.90–37.84)] (Table 4). A single SNP (rs5010528 in the HLA-C locus)
showed an association with SJS/TEN in the replication cohort (38
cases, 59 controls) [P"0.006; OR 5.12 (95% CI 1.60–16.42)].
Combining the discovery and replication cohorts strengthened the
Table 3. Logistic regression analysis of candidate SNPs in the nevirapine hypersensitivity replication cohort
Phenotype SNP Chr
Position
(GRCh37 .p13)
Genotyping
platform
Reference
allele
Associated
allele Gene
Logistic regression
P value OR (95% CI)
All hypersensitivity
(n"62)
rs34213790 6 31318579 iPLEX G A 30 of HLA-B 0.10 1.56 (0.94–2.60)
ars12112517 7 137743167 iPLEX A C AKR1D1 0.21 1.42 (0.82–2.46)
rs11988543 8 68596362 TaqMan T A CPA6 0.77 1.13 (0.54–2.28)
rs9527426 13 56208216 iPLEX T C MIR5007 0.83 1.06 (0.62–1.80)
rs35990155 23 11827017 iPLEX G T KIAA1210 0.86 0.94 (0.48–1.86)
Rash (n"27) rs10815440 9 661057 iPLEX G A KANK1 0.99 3.3%10#10 (0–1)
rs115848367 10 128045499 iPLEX A C ADAM12 0.70 1.18 (0.51–2.70)
rs74373347 12 48919428 iPLEX A G OR8S1 0.76 0.81 (0.21–3.11)
rs6511720 19 11202306 iPLEX G T LDLR 0.86 1.07 (0.51–2.24)
SJS/TEN (n"38) rs5010528 6 31241032 TaqMan A G HLA-C 0.02 5.33 (1.37–20.80)
brs150223496 15 76421885 NA G A C15orf27 NA NA
DILI (n"42) rs1730858 1 107619244 iPLEX G A NTNG1 0.61 1.57 (0.27–8.97)
crs114693001 9 76074363 TaqMan A T intergenic 0.99 2.6%10#9 (0–1)
crs142213069 13 77962182 iPLEX G C 50 of MYCBP2 0.99 2.4%10#9 (0–1)
rs6139258 20 3958616 iPLEX T C RNF24 0.03 11.17 (1.29–96.38)
SNP associations below arbitrary statistical significance (P,0.1) are highlighted in bold. NA denotes statistical analysis not applicable.
aSNPs within the association signal that are substituted from the discovery cohort SNP (high LD) due to genotyping assay design constraints.
bSNP signal where replication in the replication cohort was not possible.
cSNPs that were not be typed in the Mozambique DILI cohort (n"15 cases). Mozambique individuals were also omitted from the ‘all hypersensitivity’
analysis.
Table 4. Meta-analysis of significantly associated SNPs in the discovery and replication cohorts
SNP Gene Phenotype Cohort
Case/
control n MAF
Logistic regression Meta-analysis
P OR (95% CI) P OR (95% CI)
rs34213790 30 of
HLA-B
all
hypersensitivity
discovery case 151 0.45 1.15 % 10#6 2.34 (1.66–3.30) – –
control 182 0.37
replication case 27 0.50 0.10 1.56 (0.94–2.60) 6.69%10#7 2.06 (1.55–2.74)
control 60 0.38
rs5010528 HLA-C SJS/TEN discovery case 51 0.36 4.13%10#6 4.75 (2.45–9.22) – –
control 182 0.14
replication case 38 0.38 6.03%10#3 5.12 (1.60–16.41) 8.47%10#8 4.84 (2.71–8.61)
control 68 0.12
rs6139258 RNF24 DILI discovery case 21 0.19 6.64%10#6 14.42 (4.52–46.04) – –
control 182 0.02
replication case 42 0.07 0.03 11.17 (1.29–96.38) 5.66%10#7 13.62 (4.90–37.84)
control 68 0.01
Data shown are for analysis undertaken with covariates (CD4! cell count) included in the regression model (except DILI) for both the discovery and
replication cohorts (+ supplementary cohort for SJS/TEN and DILI).
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overall association, which approached genome-wide significance
[P"8.5%10#8, OR 4.84 (95% CI 2.71–8.61)]. No positive signals
were identified for the ‘all hypersensitivity’ phenotype (62 cases,
59 controls).
HLA-C allelotype imputation
Overall allelotype imputation from the SNP array data using
HLA*IMP demonstrated 71.5% concordance with the HLA typing
obtained for 116 of our patients using the sequence-based meth-
odology. However the ability of the imputation to correctly call
HLA-C*04:01alleles was 90%.
Within the 116 patients for which HLA allelotyping and SNP
array genotype data were available, HLA-C-04:01 allele carriage
co-occurred with the rs5010528 G allele in 112/116 cases (96.5%).
For the imputed HLA allelotype data, C*04:01 co-occurred with
rs5010528 G in 303/333 cases (91%).
The initial discovery logistic regression analysis demonstrated two
non-synonymous SNPs in the HLA-C locus associated with SJS/TEN
that were in absolute linkage disequilibrium (LD) with rs5010528
(Table 5). The first SNP (rs146911342) encodes a valine-to-
methionine amino acid substitution at residue 327 and the
second (rs1050409) encodes an alanine to glutamic acid at residue
73 (close to the peptide binding domain), which was also associated
with SJS/TEN [P"4.1%10#6, OR 4.75 (95% CI2.45–9.23)]. Both are
key defining residues of the HLA-C*04 allelotypes as defined in the
HLA-IMGT database34 and within the Malawian cohort (Figure 3).
Verification of either SNP in our discovery or replication cohorts via
other genotyping methodologies was not possible due to sequence
constraints in assay design (the proximal nucleotide sequence for pri-
mer design was not sufficiently unique or contained a restrictive
number of other genetic variants).
However, targeted sequencing of the HLA locus in 16 SJS/TEN
and 16 tolerant controls (Table 5) suggested that both the
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Figure 3. In silico docking of HLA-C*04:01 and nevirapine. (a) Specific peptide residues present in the different HLA-C allelotypes previously identified
in the Malawian cohort (n"116). – shows continuity with the reference peptide (C*04:01) and * identifies peptides not sequenced in an allelotypes. 
denotes putative nevirapine interaction and # denotes residue substituted by SNP (rs1050409) identified in GWAS. Residue reference numbers are as
defined by the in silico model. (b) HLA-C*04:01/nevirapine docking mode of conformation with the highest predicted affinity (lowest score) as pro-
duced using the PyMOL software. Key interacting residues are highlighted. (c) A LIGPLOT!40 2D schematic representation of the interaction of nevira-
pine with HLA-C*04:01 PBD residues in the highest affinity predicted docking conformation mode. The broken line indicates a hydrogen bond and
radiating lines indicate hydrophobic interactions. (d) HLA-C*04:01/nevirapine (orange) docking mode of conformation for the 20 highest predicted af-
finity (lowest scores) as produced using the PyMOL software.
GWAS of nevirapine hypersensitivity JAC
7 of 11
Ta
b
le
5
.
A
ss
o
ci
a
ti
o
n
o
f
n
ev
ir
a
p
in
e-
in
d
u
ce
d
SJ
S/
TE
N
a
n
d
im
p
u
te
d
SN
Ps
o
f
th
e
H
LA
-C
lo
cu
s
fr
o
m
th
e
m
a
in
co
h
o
rt
a
n
d
th
e
ta
rg
et
ed
se
q
u
en
ci
n
g
co
h
o
rt
SN
P
b
p
(G
R
C
h
3
7
.p
1
3
)
A
1
/A
2
A
m
in
o
a
ci
d
su
b
st
it
u
ti
o
n
G
W
A
S
(d
is
co
ve
ry
co
h
o
rt
)
Ta
rg
et
ed
se
q
u
en
ci
n
g
co
h
o
rt
ty
p
e
d
/i
m
p
u
te
d
SJ
S/
TE
N
M
A
F
(n
"
5
1
)
co
n
tr
o
lM
A
F
(n
"
1
8
2
)
P
O
R
(9
5
%
C
I)
SJ
S/
TE
N
M
A
F
(n
"
1
6
)
co
n
tr
o
lM
A
F
(n
"
1
6
)
P
O
R
(9
5
%
C
I)
LD
w
it
h
rs
5
0
1
0
5
2
8
(D
0 )
rs
1
4
6
9
1
1
3
4
2
3
1
2
3
7
7
7
9
C
/T
p
.V
3
2
7
M
im
p
u
te
d
0
.3
6
0
.1
5
4
.1
3
%
1
0
#
6
4
.7
5
(2
.4
5
–9
.2
3
)
0
.3
4
0
.1
3
0
.0
1
3
3
4
.1
4
(2
.0
7
–5
6
1
.6
)
1
rs
4
1
5
6
2
7
1
4
3
1
2
3
8
5
3
8
G
/C
im
p
u
te
d
0
.3
6
0
.1
5
4
.1
3
%
1
0
#
6
4
.7
5
(2
.4
5
–9
.2
3
)
0
.3
4
0
.1
3
0
.0
1
3
3
4
.1
4
(2
.0
7
–5
6
1
.6
)
1
rs
1
0
5
0
4
0
9
3
1
2
3
9
5
0
1
G
/T
p
.A
7
3
E
im
p
u
te
d
0
.3
6
0
.1
5
4
.1
3
%
1
0
#
6
4
.7
5
(2
.4
5
–9
.2
3
)
0
.3
4
0
.1
3
0
.0
1
3
3
4
.1
4
(2
.0
7
–5
6
1
.6
)
1
rs
4
1
5
5
3
0
1
8
3
1
2
3
9
7
4
2
G
/C
im
p
u
te
d
0
.3
6
0
.1
5
3
.7
1
%
1
0
#
6
4
.7
5
(2
.4
5
–9
.2
3
)
0
.3
4
0
.1
3
0
.0
1
3
3
4
.1
4
(2
.0
7
–5
6
1
.6
)
1
rs
4
3
6
1
6
0
9
3
1
2
4
0
6
3
5
G
/C
im
p
u
te
d
0
.3
6
0
.1
5
4
.1
3
%
1
0
#
6
4
.7
5
(2
.4
5
–9
.2
3
)
0
.3
4
0
.1
3
0
.0
1
3
3
4
.1
4
(2
.0
7
–5
6
1
.6
)
1
rs
5
0
1
0
5
2
8
3
1
2
4
1
0
3
2
A
/G
ty
p
ed
0
.3
6
0
.1
5
4
.1
3
%
1
0
#
6
4
.7
5
(2
.4
5
–9
.2
3
)
0
.3
4
0
.1
3
0
.0
1
3
3
4
.1
4
(2
.0
7
–5
6
1
.6
)
–
rs
5
8
0
1
9
8
2
3
3
1
2
4
1
2
1
5
A
/G
im
p
u
te
d
0
.3
6
0
.1
5
4
.1
3
%
1
0
#
6
4
.7
5
(2
.4
5
–9
.2
3
)
–
–
–
–
N
A
a
rs
2
5
2
4
0
8
7
3
1
2
4
1
2
9
4
C
/G
im
p
u
te
d
0
.3
7
0
.1
5
3
.7
1
%
1
0
#
6
4
.7
3
(2
.4
5
–9
.1
4
)
–
–
–
–
N
A
a
rs
5
9
1
0
3
5
0
3
3
1
2
8
7
9
4
4
G
/T
im
p
u
te
d
0
.3
7
0
.1
5
2
.7
5
%
1
0
#
6
5
.0
0
(2
.5
5
–9
.8
0
)
–
–
–
–
N
A
a
rs
7
7
6
4
1
3
2
0
3
1
2
9
8
2
2
9
C
/G
im
p
u
te
d
0
.3
5
0
.1
4
1
.6
4
%
1
0
#
6
5
.5
3
(2
.7
5
–1
1
.1
2
)
–
–
–
–
N
A
a
rs
9
4
6
8
9
6
5
3
1
3
0
0
2
4
7
T/
A
im
p
u
te
d
0
.4
4
0
.1
9
2
.2
4
%
1
0
#
6
4
.6
1
(2
.2
4
–8
.6
9
)
–
–
–
–
N
A
a
rs
3
5
3
6
4
9
8
7
3
1
3
0
9
4
2
3
T/
C
im
p
u
te
d
0
.4
9
0
.2
7
8
.0
1
%
1
0
#
6
3
.7
6
(2
.1
0
–6
.7
4
)
–
–
–
–
N
A
a
rs
3
5
4
3
5
9
4
5
3
1
3
1
1
3
7
4
T/
G
im
p
u
te
d
0
.4
9
0
.2
7
9
.8
3
%
1
0
#
6
3
.7
2
(2
.0
8
–6
.6
7
)
–
–
–
–
N
A
a
rs
3
5
2
7
8
9
3
9
3
1
3
1
9
7
8
0
G
/A
im
p
u
te
d
0
.4
7
0
.2
3
8
.0
1
%
1
0
#
6
4
.0
4
(2
.1
9
–7
.4
7
)
–
–
–
–
N
A
Th
e
lis
t
co
m
p
ri
se
s
a
ll
SN
Ps
w
it
h
a
P
va
lu
e
o
f,
1
%
1
0
#
5
in
th
e
m
a
in
co
h
o
rt
a
n
a
ly
si
s.
St
a
ti
st
ic
a
ls
ig
n
ifi
ca
n
ce
a
n
d
O
R
(9
5
%
C
I)
fo
r
th
e
ta
rg
et
ed
se
q
u
en
ci
n
g
co
h
o
rt
is
d
et
er
m
in
ed
b
y
lo
-
g
is
ti
c
re
g
re
ss
io
n
w
it
h
C
D
4
!
ce
ll
co
u
n
t
a
s
co
va
ri
a
te
.N
A
d
en
o
te
s
LD
in
d
et
er
m
in
a
b
le
in
ta
rg
et
ed
se
q
u
en
ci
n
g
co
h
o
rt
a
s
SN
P
ty
p
in
g
n
o
t
a
va
ila
b
le
.
a
SN
P
w
a
s
im
p
u
te
d
in
th
e
d
is
co
ve
ry
co
h
o
rt
a
n
a
ly
si
s
b
u
t
n
o
t
d
et
ec
te
d
a
n
d
o
r
ca
lle
d
in
th
e
se
q
u
en
ci
n
g
d
a
ta
.
Carr et al.
8 of 11
imputed non-synonymous SNPs may be in absolute LD with the
original discovery cohort signal SNP (rs5010528), again demon-
strating a significant association with nevirapine-induced SJS/TEN.
Allelotype inference from the targeted sequencing SNP data also
confirmed that both non-synonymous SNPs were in 100% co-
occurrence with HLA-C*04:01 (data not shown). Our data do not
show an association between any of the other HLA gene loci and
other nevirapine-induced hypersensitivity phenotypes.
HLA-C*04:01 and ERAP1 and ERAP2 SNP interactions
Given the previously reported interactions between ERAP genes
and HLA class I-mediated diseases, in particular ankylosing spon-
dylitis,35 we determined whether there was an interaction with the
carriage of HLA-C*04:01 using the rs5010528 G allele as a proxy
SNP (Table S1). There was no significant association (P.0.05)
between the ERAP1 variants and SJS/TEN risk in carriers of
HLA-C*04:01. However, both ERAP2 variants showed a nominal as-
sociation with SJS/TEN risk [P"0.019, OR 0.43 (95% CI 0.21–0.87)],
though this did not pass the Bonferroni threshold for multiple
testing (P"0.0125).
In silico docking
In light of the association observed between nevirapine-induced
SJS/TEN and an SNP (rs1050409) encoding an amino acid substitu-
tion at residue 73 of HLA-C (p.A73E), in silico docking was under-
taken to determine the possible effect of the residue substitution
on nevirapine binding. The data suggest that none of the predicted
modes of nevirapine docking conformation interact with residue
73, which appears to be on the periphery of the peptide-binding
domain (Figure 3). The lowest scoring (predicted highest affinity)
mode highlights an interaction between nevirapine and residues
33 and 123 in the B pocket (Figure 3). In HLA-C*04:01, residues 33
and 123 are serine and phenylalanine respectively (Figure 3). The
majority of other allelotypes do not possess these particular resi-
dues (with the exception of C*04:07 and C*14:02). Docking of the
metabolite 12-hydroxy-nevirapine was also undertaken, since it
has also been suggested as potentially responsible for nevirapine-
induced adverse drug reactions;36 these were in general agree-
ment with those for nevirapine, in that docking seems to take place
around the B pocket (e.g. near residues 33 and 123), but with more
variability in the different modes predicted than for nevirapine.
None of the predicted modes interacted with residue 73 (data not
shown). Taken together, the docking results suggest that binding
of either nevirapine or 12-hydroxy-nevirapine around the centre of
the peptide-binding regions is likely to be important in the mech-
anism of the immune-mediated reaction.
Discussion
The investigation of genetic factors predisposing to serious adverse
drug reactions is challenging because of their rarity. Despite this,
we have assembled one of the largest cohorts of patients with
clinically well-characterized nevirapine hypersensitivity, including
SJS/TEN. GWAS analysis of our Malawian discovery cohort
(n"333) identified 15 polymorphisms having a suggestive associ-
ation with nevirapine hypersensitivity (Table 2). Subsequent ana-
lysis of these variants in our replication cohort suggested that
three of the SNPs may be potential risk factors (Table 3):
rs34213790 30 of the HLA-B gene locus with all hypersensitivity
phenotypes; rs5010528 in the HLA-C gene locus with SJS/TEN, and
rs6139258 in the RNF24 gene locus with DILI. The weakest of the
above three association signals, SNP rs34213790, is unlikely to be
an independent marker of nevirapine hypersensitivity in general,
and its association may be due to a haplotype effect betweenHLA-
C*04:01 (rs5010528; see below) and B allelotypes.
SNP rs6139258 in the RNF24 gene locus only marginally failed
to pass the Bonferroni threshold of significance in the replication
cohort. Very little is known regarding the function of RNF24.
However, it is known that it is a protein that interacts with transient
receptor potential cation channel 6 (TRPC6),37 a receptor-
activated channel, expressed in liver cells,38 which plays a role in
cellular calcium homeostasis. TRPC6 has been suggested to play a
role in hepatoma cell-line proliferation, possibly via a cyclin D-
modulated mechanism.38 Thus RNF24 may have some biological
plausibility in the pathogenesis of nevirapine-induced liver injury,
and merits further investigation in additional patients with
nevirapine-induced DILI, and functional work to uncover the pos-
sible mechanisms (if any) of the association.
The most compelling of the three signals, rs5010528, gave an
OR of 4.84 for nevirapine-induced SJS/TEN, and was replicated in
patients from three countries (Malawi, Uganda and Mozambique)
at the Bonferroni threshold (P,0.05), approaching genome-wide
significance in the combined analysis (P"8.5%10#8) (Table 4).
SNP rs5010528 is located within the HLA-C gene locus. High co-
occurrence of rs5010528 with HLA-C*04:01 was observed (96.5%)
in 116 patients within this study who had previously been HLA
typed by sequence-based methods. The association between
nevirapine and rs5010528 (as a proxy for C*04:01) can be con-
sidered statistically significant when applying an HLA-wide signifi-
cance threshold of P,2.5%10#4. Additionally, HLA-C allelotypes
imputed from the SNP array data also showed a high co-
occurrence (91%) in the main study cohort, suggesting rs5010528
may be a good proxy forHLA-C*04:01. Thus, the GWAS data appear
to confirm our previous finding21 associating HLA-C*04:01 with
nevirapine-induced SJS/TEN. Of note, the association of rs5010528
with other hypersensitivity phenotypes was not as strong, suggest-
ing that the risk conferred by rs5010528 and thus HLA-C*04:01 is
specific for nevirapine-induced SJS/TEN. The reason for this is un-
clear, and will require further investigation.
In terms of clinical utility, rs5010528 appears to have little po-
tential as a pre-emptive genetic test. Indeed, based on a preva-
lence of SJS/TEN in our prospective cohort of 1.07% and assuming
a dominant mode of inheritance, the positive (PPV) and negative
(NPV) predictive values were 2.8% and 42.4% respectively. For the
RNF24 variant (rs6139258) the PPV, based on a prevalence of DILI
of 0.63%, is also very low (0.2%).
Only one previous GWAS investigating nevirapine hypersensitiv-
ity has been reported, but in a smaller Thai population (72 cases,
77 controls).39 Patients had a wide variety of rashes, with only 11
grade 4 cases (6.9%), which would be equivalent to our cases with
SJS/TEN. The SNP rs9461684 in the HLA-C locus was significantly
associated with nevirapine rash, but no HLA allelotype imputation
or HLA sequencing was carried out. In our data, rs9461684 is in
high LD with our top SNP, rs5010528 (D0"1.0, r2"0.972). The dis-
crepancy may be a result of the different LD patterns in the
GWAS of nevirapine hypersensitivity JAC
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different ethnic groups studied, as well as the much lower num-
bers of patients with serious skin reactions in the Thai study.
From the imputed SNP data of the discovery cohort and tar-
geted resequencing data (Table 5), it is clear that rs5010528 is
in LD with a functional non-synonymous SNP (rs1050409) that
leads to an alanine-to-glutamic acid substitution at residue 73,
which lies near to the peptide-binding domain of the HLA-C pro-
tein. However, in silico modelling suggested that this residue
does not interact with nevirapine in any docking conformation.
Two other residues of HLA-C*04:01 (33 and 123 in the model)
appear to be the key interactors in the majority of the predicted
modes of nevirapine docking (Figure 3), including the most fa-
voured. However, it should be noted that this is a predictive
model and further analysis of the HLA-C/nevirapine complex is
needed to further elucidate the potential for docking. The asso-
ciation signal at residue 73 (rs1050409) is likely to be a proxy for
the 33 and 123 residues also present in HLA-C*04:01. However,
this work has provided the first evidence that nevirapine binds
to the B pocket of HLA-C*04:01.
ERAP gene variants interact in a protective manner in HLA-
mediated diseases such as ankylosing spondylitis in individuals
who carry the risk HLA alleles.35 ERAP1 and ERAP2 are enzymes
involved in antigenic peptide precursor trimming prior to loading
into HLA class I molecules (and may thus alter the peptidome) and
may potentially also alter the expression of the risk HLA class I al-
lele. To our knowledge, this is one of the first examinations of
whether there is interaction between drug-induced HLA disease
and the ERAP genes. We were, however, unable to detect an inter-
action between ERAP1 variants and HLA-C*04:01 in African pa-
tients with SJS/TEN. However, a nominal association (P"0.019)
was observed for both ERAP2 SNPs (Table S1). A limitation of our
analysis is the small sample size, particularly given the much larger
numbers that have been studied in ankylosing spondylitis.
Nevertheless, the possibility of an association with ERAP2 is intrigu-
ing, and needs further investigation not only with nevirapine-
induced hypersensitivity, but also with other HLA-related adverse
drug reactions.
In identifying an SNP in the HLA-C locus that appears to be a
proxy for the HLA-C*04:01 allele, as a risk factor for nevirapine-
induced SJS/TEN, this study has added further weight to existing
evidence. The data generated also suggest that, in sub-Saharan
African HIV patients, no other strong, significant genetic risk factors
for nevirapine hypersensitivity exist that could be utilized as clinical
predictive markers. However, the data are valuable in terms of the
mechanistic insights they provide. Additionally, in silico analysis
has identified two putative HLA-C peptide residues that are pre-
dicted to be key for the binding of nevirapine, which warrant fur-
ther investigation as to their role in the pathogenesis of SJS/TEN.
Further work is also needed to determine the reasons for organ-
specific toxicities in different patients.
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